Melan-A Antibody (A103): sc-20032

Melan-A Antibody (A103) is a mouse monoclonal IgG1 kappa light chain antibody that detects the Melan-A protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and flow cytometry (FCM). Anti-Melan-A antibody (A103) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. Melan-A, also known as MART-1, is a melanocyte differentiation antigen that plays a crucial role in the immune response against melanoma, as this protein is specifically expressed in melanomas, melanocyte cell lines, and retinal tissues. Melan-A expression is vital because this protein serves as a target for cytotoxic T lymphocytes, which are essential for recognizing and eliminating cancer cells. Notably, Melan-A peptide is recognized by a majority of HLA-A2-restricted tumor-infiltrating lymphocytes in melanoma patients, highlighting Melan-A′s potential as a candidate for antigen-specific immunotherapy. The ability to generate antimelanoma cytotoxic T lymphocytes using Melan-A peptides underscores Melan-A′s importance in developing targeted cancer therapies, making Melan-A monoclonal antibody (A103) an invaluable tool for researchers and clinicians working in the field of cancer immunology.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Melan-A Antibody (A103) References:

1. Melan-A/MART-1-specific CD8 T cells: from thymus to tumor.  |  Pittet, MJ., et al. 2002. Trends Immunol. 23: 325-8. PMID: 12103339
2. Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells.  |  Vignard, V., et al. 2005. J Immunol. 175: 4797-805. PMID: 16177129
3. Impact of orthologous melan-A peptide immunizations on the anti-self melan-A/HLA-A2 T cell cross-reactivity.  |  Colombetti, S., et al. 2006. J Immunol. 176: 6560-7. PMID: 16709813
4. Decreased specific CD8+ T cell cross-reactivity of antigen recognition following vaccination with Melan-A peptide.  |  Appay, V., et al. 2006. Eur J Immunol. 36: 1805-14. PMID: 16761313
5. Deciphering the unusual HLA-A2/Melan-A/MART-1-specific TCR repertoire in humans.  |  Romero, P., et al. 2014. Eur J Immunol. 44: 2567-70. PMID: 25154881
6. Cerebrolysin induces hair repigmentation associated to MART-1/Melan-A reactivation.  |  Villarreal-Reyna, G., et al. 2022. Eur J Med Res. 27: 257. PMID: 36411485
7. Serological analysis of Melan-A(MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas.  |  Chen, YT., et al. 1996. Proc Natl Acad Sci U S A. 93: 5915-9. PMID: 8650193
8. Production of recombinant MART-1 proteins and specific antiMART-1 polyclonal and monoclonal antibodies: use in the characterization of the human melanoma antigen MART-1.  |  Kawakami, Y., et al. 1997. J Immunol Methods. 202: 13-25. PMID: 9075767
9. Tumor antigens recognized by T lymphocytes.  |  Van den Eynde, BJ. and Boon, T. 1997. Int J Clin Lab Res. 27: 81-6. PMID: 9266277
10. Peptides derived from self-proteins as partial agonists and antagonists of human CD8+ T-cell clones reactive to melanoma/melanocyte epitope MART1(27-35).  |  Loftus, DJ., et al. 1998. Cancer Res. 58: 2433-9. PMID: 9622085
11. Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma.  |  Busam, KJ., et al. 1998. Am J Surg Pathol. 22: 976-82. PMID: 9706977
12. Melanoma-associated antigens recognized by cytotoxic T lymphocytes.  |  Kirkin, AF., et al. 1998. APMIS. 106: 665-79. PMID: 9740504

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-Melan-A Antibody (A103) has 42 citations in a variety of scientific publications.

Primary antibodies like Anti-Melan-A Antibody (A103) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

Melan-A Antibody (A103) Specifications

Alternate Product Name: Melan-A

Product Clone Name: A103

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids:

Epitope Target: Melan-A

Epitope Species: human

Product Reactivity/Detection: Melan-A

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), FCM

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 42 citations in various scientific publications

Available Conjugates/Forms for Melan-A Antibody (A103): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin